Experimental models of high-risk bowel anastomosis in rats: A systematic review

Table 8 Chemotherapy models of high-risk anastomosis

Ref.	Year	Chemo agent	Sample size	Intervention	Test	Sampling day
Nayci et al[125]	2003	IP 5-FU	40	Electromagnetic field	Tensile strength, HP	7
Cetinkaya et al[126]	2005	IP mitomycin-C	81	GM-CSF	BPR ex situ, HP, histology (as per Ehrlich et al[25])	3
Kanellos et al[127]	2006	IP 5-FU and LEV	60	Fibrin glue	BPR ex situ, HP, macroscopic (adhesions as per van der Ham and Kort[32]), histology (as per Phillips et al[33])	8
Yildiz et al[128]	2013	5-FU and 20 Gy	60	HBOT	BPR ex situ, Weight, HP, histology (Fibrosis)	5
Arapoglou et al[129]	2017	Irinotecan	40	Iloprost	BPR ex situ, macroscopic (as per van der Ham and Kort[32]), histology (as per Phillips et al[33]), HP	8
Akyuz et al[130]	2018	5-FU IV	32	Melatonin	BPR ex situ, HP, histology, TNF-a, IL-1β	7
Ocak et al[131]	2019	HIPEC with CIS	30	PRP	BPR ex situ, HP, histology (as per Verhofstad et al[74])	7
Gorur et al[132]	2020	IP 5-FU	40	PRP	Body weight, BPR in situ, HP, histology (as per Verhofstad et al[74])	7
Buk et al[133]	2020	IP OX	30	PRP	BPR ex situ, histology (as per Verhofstad et al[74]), HP	7

IP: Intra-peritoneal; 5-FU: 5-Fluorouracil; LEV: Leucovorin; HIPEC: Hyperthermic intra-peritoneal chemotherapy; CIS: Cis-platina; OX: Oxaliplatin; GM-CSF: Granulocyte–macrophage colony stimulation factors; HBOT: Hyperbaric oxygen treatment; PRP: Platelet rich plasma; BPR: Bursting pressure; HP: Hydroxyproline; IL: Interleukin; TNF-a: Tumor necrosis factor-alpha.